When PD-L1-positive patients were classified by tumor-infiltrating immune cell enrichment (or CD8+ TIL, CD163+ TAM, and CD4+ TIL enrichment) and by necrosis harbored in tumor tissue, there was no significant difference in overall survival (Figure S7D–H). This evidence concerns the gene CD163 and neoplasm.